Product Details

These film-coated tablets meet pharmacopoeial standards, delivering dependable blood glucose control. Physicians widely prescribe this fixed-dose combination to manage type 2 diabetes, especially when metformin alone doesn’t achieve adequate glycaemic control.

The tablets combine:

• Metformin Hydrochloride (500 mg) — a biguanide that reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues
• Vildagliptin (50 mg) — a DPP-4 inhibitor that increases incretin levels, boosting insulin release and suppressing glucagon secretion in response to meals

Together, these two mechanisms complement each other. As a result, VERMET-V offers more comprehensive glycaemic control than either agent alone. Because it targets both hepatic glucose output and post-meal glucose spikes, physicians often prescribe it for patients who need step-up therapy or who haven’t responded fully to metformin monotherapy. Therefore, doctors rely on it across hospitals, diabetology clinics, and general outpatient settings.

Key Features

• Combines a biguanide with a DPP-4 inhibitor for dual-action glycaemic control
• Delivers improved stability and easy swallowing through its film coating
• Ensures accurate, validated dosing in every batch
• Suits pharmacy, hospital, and institutional supply needs
• Follows GMP-compliant manufacturing processes
• Requires a valid prescription, supporting safe, physician-guided use